CDH1 and inflammatory bowel disease: Treatment with E-cadherin activating mAbs significantly limited IBD progression in IL10-/- mice with spontaneous UC, as measured with histology, lesion severity scores, and non-invasive biomarkers fecal lipocalin 2 and albumin protein content in mice stool, implying a restoration of the barrier function (Bandyopadhyay et al., 2021).